Momenta's Humira biosimilar succeeds in key psoriasis study

(Reuters) - U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news